Short-interference RNAs: Becoming Medicines

Overview

Journal EXCLI J

Specialty Biology

Date 2015 Dec 10

PMID 26648823

Citations 7

Authors

Tamara Martinez

Ana Isabel Jimenez

Covadonga Paneda

Affiliations

Soon will be listed here.

Abstract

RNA interference is a cellular mechanism by which small molecules of double stranded RNA modulate gene expression acting on the concentration and/or availability of a given messenger RNA. Almost 10 years after Fire and Mello received the Nobel Prize for the discovery of this mechanism in flat worms, RNA interference is on the edge of becoming a new class of therapeutics. With various phase III studies underway, the following years will determine whether RNAi-therapeutics can rise up to the challenge and become mainstream medicines. The present review gives a thorough overview of the current status of this technology focusing on the path to the clinic of this new class of compounds.

Citing Articles

Co-delivery of antioxidants and siRNA-VEGF: promising treatment for age-related macular degeneration.

Dias M, Cruz-Cazarim E, Pittella F, Baiao A, Pacheco A, Sarmento B Drug Deliv Transl Res. 2025; .

PMID: 39751765 DOI: 10.1007/s13346-024-01772-x.

Dyslipidemia: A Narrative Review on Pharmacotherapy.

Oliveira L, Assis A, Giraldez V, Scudeler T, Soares P Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543075 PMC: 10975559. DOI: 10.3390/ph17030289.

Connective Tissue Growth Factor: From Molecular Understandings to Drug Discovery.

Chen Z, Zhang N, Chu H, Yu Y, Zhang Z, Zhang G Front Cell Dev Biol. 2020; 8:593269.

PMID: 33195264 PMC: 7658337. DOI: 10.3389/fcell.2020.593269.

Introducing an In Vitro Liver Stability Assay Capable of Predicting the In Vivo Pharmacodynamic Efficacy of siRNAs for IVIVC.

Basiri B, Xie F, Wu B, Humphreys S, Lade J, Thayer M Mol Ther Nucleic Acids. 2020; 21:725-736.

PMID: 32771924 PMC: 7415771. DOI: 10.1016/j.omtn.2020.07.012.

The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies.

Janas M, Harbison C, Perry V, Carito B, Sutherland J, Vaishnaw A Toxicol Pathol. 2018; 46(7):735-745.

PMID: 30139307 PMC: 6249674. DOI: 10.1177/0192623318792537.

References

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

Peacock H, Kannan A, Beal P, Burrows C . Chemical modification of siRNA bases to probe and enhance RNA interference. J Org Chem. 2011; 76(18):7295-300. PMC: 3170502. DOI: 10.1021/jo2012225. View

Strebhardt K, Ullrich A . Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006; 6(4):321-30. DOI: 10.1038/nrc1841. View

McKenzie R, Fried M, Sallie R, Conjeevaram H, Di Bisceglie A, Park Y . Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995; 333(17):1099-105. DOI: 10.1056/NEJM199510263331702. View

Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y . Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008; 26(4):431-42. DOI: 10.1038/nbt1396. View

Liu Q, Zhou H, Zhang K, Shi X, Fan W, Zhu R . In silico target-specific siRNA design based on domain transfer in heterogeneous data. PLoS One. 2013; 7(12):e50697. PMC: 3528743. DOI: 10.1371/journal.pone.0050697. View

Cheng A, Li M, Liang Y, Wang Y, Wong L, Chen C . Stem-loop RT-PCR quantification of siRNAs in vitro and in vivo. Oligonucleotides. 2009; 19(2):203-8. DOI: 10.1089/oli.2008.0176. View

Demidov V, Potaman V, Frank-Kamenetskii M, Egholm M, Buchard O, Sonnichsen S . Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol. 1994; 48(6):1310-3. DOI: 10.1016/0006-2952(94)90171-6. View

Johnson A, Ray A, Hanes J, Suo Z, Colacino J, Anderson K . Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem. 2001; 276(44):40847-57. DOI: 10.1074/jbc.M106743200. View

10.

Larsson E, Sander C, Marks D . mRNA turnover rate limits siRNA and microRNA efficacy. Mol Syst Biol. 2010; 6:433. PMC: 3010119. DOI: 10.1038/msb.2010.89. View

11.

John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D . Human MicroRNA targets. PLoS Biol. 2004; 2(11):e363. PMC: 521178. DOI: 10.1371/journal.pbio.0020363. View

12.

Chu C, Rana T . Potent RNAi by short RNA triggers. RNA. 2008; 14(9):1714-9. PMC: 2525957. DOI: 10.1261/rna.1161908. View

13.

Nakai N, Kishida T, Shin-Ya M, Imanishi J, Ueda Y, Kishimoto S . Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther. 2006; 14(4):357-65. DOI: 10.1038/sj.gt.3302868. View

14.

Chang C, Yoo J, Hong S, Lee S, Kang H, Sun X . Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther. 2009; 17(4):725-32. PMC: 2835116. DOI: 10.1038/mt.2008.298. View

15.

Reynolds A, Leake D, Boese Q, Scaringe S, Marshall W, Khvorova A . Rational siRNA design for RNA interference. Nat Biotechnol. 2004; 22(3):326-30. DOI: 10.1038/nbt936. View

16.

Prakash T, Allerson C, Dande P, Vickers T, Sioufi N, Jarres R . Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem. 2005; 48(13):4247-53. DOI: 10.1021/jm050044o. View

17.

Klingelhoefer J, Moutsianas L, Holmes C . Approximate Bayesian feature selection on a large meta-dataset offers novel insights on factors that effect siRNA potency. Bioinformatics. 2009; 25(13):1594-601. PMC: 2940241. DOI: 10.1093/bioinformatics/btp284. View

18.

Judge A, Sood V, Shaw J, Fang D, McClintock K, MacLachlan I . Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005; 23(4):457-62. DOI: 10.1038/nbt1081. View

19.

Kleinman M, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi J . Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452(7187):591-7. PMC: 2642938. DOI: 10.1038/nature06765. View

20.

Henry S, Jagels M, Hugli T, Manalili S, Geary R, Giclas P . Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Nucleic Acid Ther. 2014; 24(5):326-35. DOI: 10.1089/nat.2014.0491. View